Amylyx Pharmaceuticals (AMLX) EBIT: 2021-2025
Historic EBIT for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$36.0 million.
- Amylyx Pharmaceuticals' EBIT rose 52.38% to -$36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.3 million, marking a year-over-year increase of 42.18%. This contributed to the annual value of -$314.7 million for FY2024, which is 911.12% down from last year.
- According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' EBIT is -$36.0 million, which was up 15.94% from -$42.9 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' EBIT registered a high of $20.2 million during Q2 2023, and its lowest value of -$122.1 million during Q1 2024.
- For the 3-year period, Amylyx Pharmaceuticals' EBIT averaged around -$35.7 million, with its median value being -$37.8 million (2025).
- Per our database at Business Quant, Amylyx Pharmaceuticals' EBIT spiked by 137.23% in 2023 and then slumped by 5,848.86% in 2024.
- Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' EBIT stood at -$28.3 million in 2021, then tumbled by 57.49% to -$44.6 million in 2022, then skyrocketed by 104.34% to $1.9 million in 2023, then slumped by 2,202.07% to -$40.7 million in 2024, then surged by 52.38% to -$36.0 million in 2025.
- Its EBIT was -$36.0 million in Q3 2025, compared to -$42.9 million in Q2 2025 and -$37.8 million in Q1 2025.